Literature DB >> 20861008

Determinants of affinity and proteolytic stability in interactions of Kunitz family protease inhibitors with mesotrypsin.

Moh'd A Salameh1, Alexei S Soares, Duraiswamy Navaneetham, Dipali Sinha, Peter N Walsh, Evette S Radisky.   

Abstract

An important functional property of protein protease inhibitors is their stability to proteolysis. Mesotrypsin is a human trypsin that has been implicated in the proteolytic inactivation of several protein protease inhibitors. We have found that bovine pancreatic trypsin inhibitor (BPTI), a Kunitz protease inhibitor, inhibits mesotrypsin very weakly and is slowly proteolyzed, whereas, despite close sequence and structural homology, the Kunitz protease inhibitor domain of the amyloid precursor protein (APPI) binds to mesotrypsin 100 times more tightly and is cleaved 300 times more rapidly. To define features responsible for these differences, we have assessed the binding and cleavage by mesotrypsin of APPI and BPTI reciprocally mutated at two nonidentical residues that make direct contact with the enzyme. We find that Arg at P(1) (versus Lys) favors both tighter binding and more rapid cleavage, whereas Met (versus Arg) at P'(2) favors tighter binding but has minimal effect on cleavage. Surprisingly, we find that the APPI scaffold greatly enhances proteolytic cleavage rates, independently of the binding loop. We draw thermodynamic additivity cycles analyzing the interdependence of P(1) and P'(2) substitutions and scaffold differences, finding multiple instances in which the contributions of these features are nonadditive. We also report the crystal structure of the mesotrypsin·APPI complex, in which we find that the binding loop of APPI displays evidence of increased mobility compared with BPTI. Our data suggest that the enhanced vulnerability of APPI to mesotrypsin cleavage may derive from sequence differences in the scaffold that propagate increased flexibility and mobility to the binding loop.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20861008      PMCID: PMC2978618          DOI: 10.1074/jbc.M110.171348

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  87 in total

Review 1.  Evolutionary families of peptidase inhibitors.

Authors:  Neil D Rawlings; Dominic P Tolle; Alan J Barrett
Journal:  Biochem J       Date:  2004-03-15       Impact factor: 3.857

2.  Human mesotrypsin exhibits restricted S1' subsite specificity with a strong preference for small polar side chains.

Authors:  Edit Szepessy; Miklós Sahin-Tóth
Journal:  FEBS J       Date:  2006-06-05       Impact factor: 5.542

3.  Proteolytic inactivation of tissue factor pathway inhibitor by bacterial omptins.

Authors:  Thomas H Yun; Jessica E Cott; Richard I Tapping; James M Slauch; James H Morrissey
Journal:  Blood       Date:  2008-11-06       Impact factor: 22.113

4.  The effect of leukocyte elastase on tissue factor pathway inhibitor.

Authors:  D A Higuchi; T C Wun; K M Likert; G J Broze
Journal:  Blood       Date:  1992-04-01       Impact factor: 22.113

5.  Regional distribution of human trypsinogen 4 in human brain at mRNA and protein level.

Authors:  Júlia Tóth; Erika Siklódi; Péter Medveczky; Katalin Gallatz; Péter Németh; László Szilágyi; László Gráf; Miklós Palkovits
Journal:  Neurochem Res       Date:  2007-04-04       Impact factor: 3.996

6.  On the size of the active site in proteases. I. Papain.

Authors:  I Schechter; A Berger
Journal:  Biochem Biophys Res Commun       Date:  1967-04-20       Impact factor: 3.575

7.  Mesotrypsin, a brain trypsin, activates selectively proteinase-activated receptor-1, but not proteinase-activated receptor-2, in rat astrocytes.

Authors:  Yingfei Wang; Weibo Luo; Thomas Wartmann; Walter Halangk; Miklós Sahin-Tóth; Georg Reiser
Journal:  J Neurochem       Date:  2006-08-11       Impact factor: 5.372

8.  Identification and expression of the cDNA-encoding human mesotrypsin(ogen), an isoform of trypsin with inhibitor resistance.

Authors:  C N Nyaruhucha; M Kito; S I Fukuoka
Journal:  J Biol Chem       Date:  1997-04-18       Impact factor: 5.157

9.  S100 family members and trypsinogens are predictors of distant metastasis and survival in early-stage non-small cell lung cancer.

Authors:  Sven Diederichs; Etmar Bulk; Björn Steffen; Ping Ji; Lara Tickenbrock; Kerstin Lang; Kurt S Zänker; Ralf Metzger; Paul M Schneider; Volker Gerke; Michael Thomas; Wolfgang E Berdel; Hubert Serve; Carsten Müller-Tidow
Journal:  Cancer Res       Date:  2004-08-15       Impact factor: 12.701

10.  Mast cell tissue inhibitor of metalloproteinase-1 is cleaved and inactivated extracellularly by alpha-chymase.

Authors:  B T Frank; J C Rossall; G H Caughey; K C Fang
Journal:  J Immunol       Date:  2001-02-15       Impact factor: 5.422

View more
  28 in total

Review 1.  Biochemical and structural insights into mesotrypsin: an unusual human trypsin.

Authors:  Moh'd A Salameh; Evette S Radisky
Journal:  Int J Biochem Mol Biol       Date:  2013-09-13

2.  Mesotrypsin Has Evolved Four Unique Residues to Cleave Trypsin Inhibitors as Substrates.

Authors:  Alexandre P Alloy; Olumide Kayode; Ruiying Wang; Alexandra Hockla; Alexei S Soares; Evette S Radisky
Journal:  J Biol Chem       Date:  2015-07-14       Impact factor: 5.157

3.  An Acrobatic Substrate Metamorphosis Reveals a Requirement for Substrate Conformational Dynamics in Trypsin Proteolysis.

Authors:  Olumide Kayode; Ruiying Wang; Devon F Pendlebury; Itay Cohen; Rachel D Henin; Alexandra Hockla; Alexei S Soares; Niv Papo; Thomas R Caulfield; Evette S Radisky
Journal:  J Biol Chem       Date:  2016-11-03       Impact factor: 5.157

4.  The P(2)' residue is a key determinant of mesotrypsin specificity: engineering a high-affinity inhibitor with anticancer activity.

Authors:  Moh'd A Salameh; Alexei S Soares; Alexandra Hockla; Derek C Radisky; Evette S Radisky
Journal:  Biochem J       Date:  2011-11-15       Impact factor: 3.857

5.  The crystal structure of a multidomain protease inhibitor (HAI-1) reveals the mechanism of its auto-inhibition.

Authors:  Min Liu; Cai Yuan; Jan K Jensen; Baoyu Zhao; Yunbin Jiang; Longguang Jiang; Mingdong Huang
Journal:  J Biol Chem       Date:  2017-03-27       Impact factor: 5.157

6.  Inactivation of mesotrypsin by chymotrypsin C prevents trypsin inhibitor degradation.

Authors:  Vanda Toldi; András Szabó; Miklós Sahin-Tóth
Journal:  J Biol Chem       Date:  2020-02-03       Impact factor: 5.157

7.  PRSS3/mesotrypsin is a therapeutic target for metastatic prostate cancer.

Authors:  Alexandra Hockla; Erin Miller; Moh'd A Salameh; John A Copland; Derek C Radisky; Evette S Radisky
Journal:  Mol Cancer Res       Date:  2012-12       Impact factor: 5.852

8.  Disulfide engineering of human Kunitz-type serine protease inhibitors enhances proteolytic stability and target affinity toward mesotrypsin.

Authors:  Itay Cohen; Matt Coban; Anat Shahar; Banumathi Sankaran; Alexandra Hockla; Shiran Lacham; Thomas R Caulfield; Evette S Radisky; Niv Papo
Journal:  J Biol Chem       Date:  2019-01-30       Impact factor: 5.157

9.  Combinatorial protein engineering of proteolytically resistant mesotrypsin inhibitors as candidates for cancer therapy.

Authors:  Itay Cohen; Olumide Kayode; Alexandra Hockla; Banumathi Sankaran; Derek C Radisky; Evette S Radisky; Niv Papo
Journal:  Biochem J       Date:  2016-03-08       Impact factor: 3.857

10.  Crystal structures of matriptase in complex with its inhibitor hepatocyte growth factor activator inhibitor-1.

Authors:  Baoyu Zhao; Cai Yuan; Rui Li; Dan Qu; Mingdong Huang; Jacky Chi Ki Ngo
Journal:  J Biol Chem       Date:  2013-02-26       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.